Linear IgA disease (LAD) is rare and there are only a few cases reported where its lesions were limited to the oral mucosa. Eosinophilic granulomatosis with polyangiitis (EGPA) is also a rare multisystemic disease. Therefore, the occurrence of LAD and EGPA in the same patient is very rare.
Linear immunoglobulin A disease (LAD) is a rare subepithelial blistering autoimmune disorder characterized by linear deposits of IgA along the basement membrane zone. 1, 2 LAD predominantly affects the skin and mucous membranes; however, the occurrence of lesions limited to the oral mucosa is rare. 3 Most LAD cases are idiopathic; however, certain drugs, infections, trauma, autoimmune disorders and malignancies can be potential inducers. [3] [4] [5] [6] Some authors have proposed that it may be precipitated by diclofenac, 6 lithium carbonate, 7 statins, 8 piroxicam, 9 acetaminophen, 10 amiodarone, 11 ampicillin/sulbactam, 12 metronidazole, 13 amoxicillin-clavulanic acid, 14 interferon-2a, 15 trimethoprim-sulfamethoxazole 16 and vancomycin. 17 LAD have shown oral manifestation such as desquamative gingivitis, persistence of ulceration and the management of the oral lesions are very difficult. 18 Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystemic disorder that affects small-to-medium-sized vessels and is associated with severe asthma and eosinophilia. 19 The pathogenesis of EGPA is still unknown but eosinophils are the most characteristic cells in this disease. Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis of the small vessels, especially glomerulonephritis, is another feature of EGPA. 20, 21 Generalized severe alveolar bone loss in an LAD/EGPA case has never been reported.
Case report
A 24-year-old female patient was referred to the clinic of the Department of Oral Medicine in 2014 with complaints of a burning sensation and bullous eruption in the oral cavity during the past 2 years. She was initially diagnosed with idiopathic thrombocytopenic purpura (ITP) in 2010, and was treated with dapsone by her physicians. However, she developed a severe hypersensitivity reaction on the skin and subsequently received 60 mg/day prednisolone. After treatment, the skin showed improvement. In 2011, she went to the dentist for orthodontic treatment and during treatment, bullous eruptions began in the oral cavity along with slight tooth mobility. The history of tooth mobility was unclear, however, it gradually developed during her orthodontic treatment. Despite this mobility, successful minor tooth movement was completed within that year. In 2014, a biopsy specimen taken from her lesion showed IgA deposited at the basement membrane and LAD was diagnosed by her physician. Because the lesions were limited to the oral mucosa, her physician referred her to our clinic for treatment.
At the patient's first visit in 2014, an extraoral examination showed generalized skin hypopigmentation and nail grooves. Intraoral examination showed blood filled bullae on the gingiva at the maxillary right second premolar and left lateral incisor, and petechial hemorrhage on the lingual gingiva of her mandibular anterior teeth and the dorsal surface of the tongue ( Fig. 1a-d ). We referred her to the Periodontology Department for treatment. Fluocinolone acetonide 0.1% with clotrimazole gel was prescribed to apply on the lesions and an oral hygiene check-up was performed. Her symptoms and bullae showed improvement. She did not attend follow-up visits and returned to our clinic in July 2016. At that time, the oral lesions were worse and we referred her to a dermatologist for further treatment.
Interestingly, during 2010-2016, she developed arthritis, glaucoma, abnormal menstruation, eosinophilia, hypothyroidism, asthma, respiratory tract involvement, and glomerulonephritis. Based on these findings, her physicians diagnosed her systemic disease as eosinophilic granulomatosis with polyangiitis (EGPA) and treated her with mycophenolate mofetil 500 mg 1 tablet b.i.d., tacrolimus 0.5 mg 1 tablet o.d., prednisolone 1 tablet o.d., levothyroxine 0.1 mg 1 tablet o.d., enalapril 5 mg ½ tablet o.d., simvastatin 10 mg 1 tablet h.s., and vitamin D (20,000 U) 1 tablet weekly. In December 2016, she returned to our clinic with chief complaints of a burning sensation and bullous rupture in the oral cavity without skin lesions. Generalized erythematous gingiva and 5 mm and 3 mm blood filled bullae on the right buccal mucosa were observed. Ruptured 8 × 3 mm bullae were found on the right and the left hard palate areas of the second molar ( Fig.  2a-c) . Triamcinolone acetonide 0.1% mouthwash was prescribed to treat the oral lesions, however, the lesions only showed slight improvement. The timeline of the Fig. 3 . Timeline of the occurrence of the oral lesions and developing diseases occurrence of the oral lesions and developing diseases is shown in Fig. 3 .
Oral radiographic findings showed internal root resorption of the maxillary right second premolar and generalized severe alveolar bone loss between the first visit in 2014 and the 2-year follow-up ( Fig. 4-6 ). Although the internal root resorption size was similar to that observed at the first visit, the patient demonstrated generalized progressive bone loss since her initial visit. In addition, many teeth showed apical root resorption. 
Discussion
Vesiculobullous lesions are common in the oral mucosa; however, LAD is a rare disease. The involvement of only the oral mucosa in LAD is rare and commonly presents as desquamative gingivitis. 3, 22, 23 However, LAD treatment does not always control the progression of the disease. To our knowledge, this is the first case of LAD and EGPA associated with severe alveolar bone loss and internal root resorption. The patient was initially treated for ITP with dapsone. Surprisingly, dapsone, which is a bacteriostatic, anti-inflammatory, and immunomodulating agent, is a drug used in the treatment of LAD, 1 however, this patient developed LAD after dapsone treatment. Although dapsone is frequently prescribed compared to other second-line treatments that can be an option for the less severe form of ITP, 24 a severe allergic reaction erupted on her skin. Therefore, the physicians treated her with 60 mg/day prednisolone and gradually reduced the prednisolone dosage when the skin showed hypopigmentation. From her medical history, following treatment of ITP with dapsone, the patient developed LAD. Although the etiology of drug-induced LAD remains unclear, it might be caused by an immune response from drug-derived hapten-protein antigens. However, because drug- Fig. 6 . Panoramic radiograph from December 2016 demonstrating that many teeth had been extracted, however, the internal root resorption on the maxillary right second premolar was still the same size induced LAD is more severe than spontaneous LAD, we cannot rule out that her LAD developed spontaneously. 25 Since the first visit, this patient had developed many systemic diseases. EGPA was ultimately diagnosed by her physicians. EGPA, or Churg-Strauss syndrome (CSS), is characterized by disseminated necrotizing vasculitis with extravascular granulomas occurring in patients with asthma and tissue eosinophilia. 26 EGPA is also a rare disease with an incidence in Europe of 0.5-6.8 new cases/year per million people; however, a case of EGPA in a Thai patient has never been reported. This disease most commonly affects subjects between 40-60 year-old, with a mean age at diagnosis of 48 years. 19 Other manifestations of EGPA include major salivary gland involvement with the development of a focal mass or enlargement and neurolaryngeal involvement with dysphonia. [27] [28] [29] [30] Treatment of patients with EGPA must be performed by experienced physicians who are specialists in rare autoimmune diseases. A combination of high dose corticosteroids and cyclophosphamide remains the gold standard for the treatment of severe EGPA cases; however, the use of biological agents such as rituximab or mepolizumab seems to be a promising therapeutic alternative. 20, 26 Our patient's oral radiographic findings showed internal root resorption of the maxillary right second premolar and generalized severe alveolar bone loss between the first visit and the 2-year follow-up. An excessive loss of crestal bone height is almost never seenas a complication of orthodontic treatment and minimal effects on crestal bone level are observed during longterm follow up. 31 The severe alveolar bone loss may be due to the disseminated necrotizing vasculitis that can occur in EGPA. Therefore, it is unreasonable to suspect that the periodontitis in this case occurred from orthodontic force 3 years after treatment was completed. Thus, based on the patient's history, clinical attachment loss and radiographic images, aggressive generalized periodontitis in the course of EGPA was the diagnosis in this case. However, this case was difficult to manage from a periodontal perspective. Conventional periodontal treatment was performed by a periodontist since 2014, however, there was no improvement due to her EGPA involvement. Moreover, the patient did not come for follow-up visits for 3 years, therefore, rapid periodontal progression was seen in almost all teeth. Periodontal treatment was ineffective in halting the progression of the patient's generalized alveolar bone loss. Multiple teeth were extracted because of mobility from severe bone loss. Many teeth showed apical root resorption that could have resulted from orthodontic force during fixed orthodontic treatment. A previous systematic review concluded that comprehensive orthodontic treatment increased the incidence and severity of root resorption, with heavy forces being particularly harmful. 32 In our case, it might be possible that EPGA can cause severe bone loss. However, the size of the internal root resorption lesions was similar to that at her first visit.
Conclusion
This case report presents the very rare finding of both LAD and EGPA in the same patient. In addition, this is the first report of a case of LAD and EGPA associated with severe generalized alveolar bone loss and internal root resorption. Moreover, the progression of the generalized severe alveolar bone loss in this case could not be prevented.
